Share This Page
SECRETIN-FERRING Drug Patent Profile
✉ Email this page to a colleague
When do Secretin-ferring patents expire, and when can generic versions of Secretin-ferring launch?
Secretin-ferring is a drug marketed by Ferring and is included in one NDA.
The generic ingredient in SECRETIN-FERRING is secretin. There are six drug master file entries for this compound. Additional details are available on the secretin profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SECRETIN-FERRING?
- What are the global sales for SECRETIN-FERRING?
- What is Average Wholesale Price for SECRETIN-FERRING?
Summary for SECRETIN-FERRING
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 11 |
| Patent Applications: | 110 |
| DailyMed Link: | SECRETIN-FERRING at DailyMed |
US Patents and Regulatory Information for SECRETIN-FERRING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferring | SECRETIN-FERRING | secretin | INJECTABLE;INJECTION | 018290-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: SECRETIN-FERRING
Introduction
In the evolving landscape of pharmacology, Secretin-Ferring emerges as a niche yet potentially transformative therapeutic agent primarily anchored in gastrointestinal and diagnostic applications. Its market trajectory hinges upon various factors including clinical efficacy, regulatory pathways, competitor landscape, and evolving healthcare demands. This analysis dissects these vectors to depict a comprehensive picture of the market dynamics and financial prospects for Secretin-Ferring.
Overview of Secretin-Ferring
Secretin-Ferring is a synthetic formulation mimicking natural secretin hormone, originally derived from the porcine or human sources. It functions primarily in diagnostic assays of pancreatic and biliary functions, and potentially in therapeutic contexts related to exocrine pancreatic insufficiency or related gastrointestinal dysfunctions. Its current clinical applications are centered around pancreatic function testing, a niche but essential diagnostic segment.
Ferring Pharmaceuticals, a global biopharmaceutical company specializing in reproductive health, urology, and gastroenterology, oversees the development, manufacturing, and commercialization of Secretin-Ferring. Its proprietary positioning emphasizes safety, reliability, and regulatory compliance, which underpin its strategic market entry.
Market Dynamics
1. Clinical Efficacy and Regulatory Landscape
Secretin-Ferring's market penetration correlates heavily with advancements in diagnostic protocols and regulatory approvals. The drug's efficacy in pancreatic function tests aligns with the increasing need for precise diagnostics in chronic pancreatitis, cystic fibrosis, and other pancreatic diseases.
Regulatory acceptance by agencies such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) substantially influences market growth. Recent approvals or clearances facilitate broader adoption and clinical confidence. In some jurisdictions, off-label use may augment revenues, but regulatory clarity remains essential for sustainable growth.
2. Diagnostic Market Expansion
The global diagnostic market for pancreatic function tests is projected to expand at a CAGR of approximately 5% through 2030, driven by rising prevalence of pancreatic diseases and greater access to advanced diagnostic tools in emerging markets.
Secretin-based diagnostic agents benefit from technological enhancements—such as minimally invasive testing methods and improved assay sensitivities—that heighten clinical adoption. Furthermore, increased awareness among gastroenterologists enhances demand, especially in developed healthcare systems.
3. Therapeutic Potential and Pipeline Development
Current applications of Secretin-Ferring are diagnostic; however, ongoing research explores its therapeutic potential in conditions such as exocrine pancreatic insufficiency and gastrointestinal motility disorders. These emerging indications could significantly diversify revenue streams, especially if clinical trials demonstrate efficacy.
The drug's future financial trajectory depends on successful clinical trials, positive regulatory outcomes, and subsequent approval for therapeutic indications, which could propel its market valuation into higher segments of gastroenterological therapeutics.
4. Competitive Landscape
Key competitors include other pancreatic function test agents, such as calcium stimulation tests, and emerging novel diagnostics utilizing imaging technologies. Companies specializing in gastrointestinal diagnostics—like Medtronic or Cook Medical—may introduce alternatives, potentially eroding market share.
However, Secretin-Ferring’s established safety profile, combined with clinician familiarity, offers a competitive moat. Continuous innovation and strategic partnerships could further sustain its position.
5. Pricing, Reimbursement, and Market Access
Pricing strategies substantially impact revenue. With diagnostic tests often reimbursed variably across regions, securing favorable reimbursement agreements is crucial. Payer dynamics, especially in the U.S. and Europe, are gradually shifting toward value-based healthcare, necessitating clear evidence of clinical benefit and cost-effectiveness.
Market access negotiations, particularly in emerging economies, hinge on local healthcare infrastructure and regulatory policies, influencing the geographic expansion and revenue potential.
Financial Trajectory
1. Revenue Growth Drivers
The primary revenue driver remains clinical diagnostics, propelled by increasing disease prevalence and test adoption. As of 2023, estimates suggest a conservative revenue growth of around 4-6% annually, aligning with diagnostic market trends.
The potential therapeutic applications, still in investigational phases, could significantly amplify revenues if early-stage trials succeed. A successful pivot into therapeutics could introduce multi-year revenue streams, with potential blockbuster status if indications prove sufficiently lucrative.
2. Cost Considerations
Development costs include R&D investments, regulatory filing fees, and manufacturing scale-up. Operating costs are influenced by supply chain efficiencies and marketing efforts. Cost containment measures and strategic licensing agreements can improve margins.
Manufacturing scale is pivotal; economies of scale may reduce per-unit costs, boosting profitability. Any regulatory delays or adverse trial outcomes could increase costs and dampen financial outlooks.
3. Investment and Strategic Partnerships
Ferring's strategic collaborations—either with biotech firms or academic institutions—are instrumental in accelerating clinical development and expanding geographic reach. Licensing agreements with regional players can facilitate market entry in emerging markets, diversifying revenue.
Additionally, securing funding through venture capital, grants, or public offerings will support ongoing R&D initiatives, especially in therapeutic pipeline development.
4. Long-term Outlook
The transition from a primarily diagnostic agent to a dual diagnostic-therapeutic franchise could redefine Secretin-Ferring's financial trajectory, transforming it into a multi-billion-dollar asset over the next decade. Realistically, the current market outlook suggests a steady, moderate income stream, with growth potential tied to clinical success and regulatory milestones.
Market Risks and Opportunities
Risks:
- Regulatory hurdles delaying approvals or restricting indications
- Competitive innovations reducing the test's clinical and economic value
- Reimbursement challenges in cost-sensitive markets
- Clinical trial failures impeding therapeutic development
Opportunities:
- Expanding indications into therapeutic domains
- Advances in non-invasive diagnostics increasing adoption
- Strategic alliances bolstering market presence
- Growing global burden of chronic pancreatic diseases
Key Takeaways
-
Growing Diagnostic Demand: The increasing prevalence of pancreatic and gastrointestinal disorders supports sustained demand for Secretin-Ferring’s diagnostic applications.
-
Regulatory and Clinical Validation: Regulatory approvals and robust clinical data are pivotal to market expansion, especially for novel therapeutic uses.
-
Pipeline Diversification: Success in clinical trials for therapeutic indications can markedly elevate the drug's market value and revenue streams.
-
Market Access and Reimbursement: Clear pathways for reimbursement and strategic market access are crucial for revenue optimization, particularly across diverse geographic regions.
-
Competitive and Innovation Strategies: Continuous innovation, strategic alliances, and differentiated positioning will mitigate competitive risks and open new markets.
FAQs
1. What are the primary clinical applications of Secretin-Ferring?
Secretin-Ferring is mainly used in diagnostic testing to evaluate pancreatic exocrine function, aiding in the diagnosis of conditions such as chronic pancreatitis and cystic fibrosis.
2. How does regulatory approval influence Secretin-Ferring’s market potential?
Approval from agencies like the FDA and EMA facilitates clinical adoption by validating safety and efficacy, expanding indications, and enabling reimbursement, thereby directly impacting sales and market share.
3. What is the growth outlook for Secretin-Ferring's therapeutic pipeline?
While still experimental, successful clinical trials could propel therapeutic indications, significantly broadening revenue opportunities and elevating its market status over the next 5–10 years.
4. How does competition from emerging diagnostics affect Secretin-Ferring?
Innovations such as imaging-based diagnostics and alternative biomarkers pose competitive threats. However, Secretin-Ferring’s established clinical track record and clinician familiarity provide a competitive buffer.
5. What strategic moves can enhance Secretin-Ferring’s financial trajectory?
Investments in R&D, securing regulatory approvals, forming strategic alliances, expanding into emerging markets, and engaging with payers for favorable reimbursement will strengthen its market and financial position.
Conclusion
Secretin-Ferring occupies a strategic niche within the gastroenterological diagnostics sphere, with growth driven by increasing disease prevalence, technological advancements, and expanding clinical applications. Its future financial trajectory hinges on regulatory success, pipeline progress, and market penetration strategies. Proactive engagement with evolving healthcare paradigms and innovation pipelines positions Secretin-Ferring for sustained growth, potentially transforming it from a diagnostic agent to a multifaceted therapeutic entity.
References
[1] Market Analysis Reports, "Gastrointestinal Diagnostic Market Outlook 2022-2030," Global Industry Analysts.
[2] Ferring Pharmaceuticals Annual Reports, 2022.
[3] Regulatory Agency Publications, "FDA & EMA Approvals in Gastroenterology," 2022.
[4] Clinical Trials Data, "Assessing the Therapeutic Potential of Secretin in Pancreatic Disorders," ClinicalTrials.gov.
[5] Industry Expert Commentary, "The Future of Gastrointestinal Diagnostics," Healthcare Innovation Journal, 2022.
More… ↓
